Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 535

1.

Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.

Wang Y, Hardin H, Chu YH, Esbona K, Zhang R, Lloyd RV.

Endocr Pathol. 2019 Aug 29. doi: 10.1007/s12022-019-09589-y. [Epub ahead of print]

PMID:
31468286
2.

In situ hybridization: Introduction to techniques, applications and pitfalls in the performance and interpretation of assays.

Chu YH, Hardin H, Zhang R, Guo Z, Lloyd RV.

Semin Diagn Pathol. 2019 Sep;36(5):336-341. doi: 10.1053/j.semdp.2019.06.004. Epub 2019 Jun 12. Review.

PMID:
31227426
3.

Parathyroid Neoplasms: Immunohistochemical Characterization and Long Noncoding RNA (lncRNA) Expression.

Yu Q, Hardin H, Chu YH, Rehrauer W, Lloyd RV.

Endocr Pathol. 2019 Jun;30(2):96-105. doi: 10.1007/s12022-019-9578-3.

PMID:
31119524
4.

Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.

Starenki D, Sosonkina N, Hong SK, Lloyd RV, Park JI.

Int J Mol Sci. 2019 Apr 26;20(9). pii: E2069. doi: 10.3390/ijms20092069.

5.

In Situ Hybridization Analysis of Long Non-coding RNAs MALAT1 and HOTAIR in Gastroenteropancreatic Neuroendocrine Neoplasms.

Chu YH, Hardin H, Eickhoff J, Lloyd RV.

Endocr Pathol. 2019 Mar;30(1):56-63. doi: 10.1007/s12022-018-9564-1.

PMID:
30600442
6.

Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.

Roy M, Buehler DG, Zhang R, Schwalbe ML, Baus RM, Salamat MS, Lloyd RV, Rosenbaum JN.

Endocr Pathol. 2019 Mar;30(1):35-42. doi: 10.1007/s12022-018-9559-y.

PMID:
30523500
7.

Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.

Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE.

JAMA Oncol. 2019 Feb 1;5(2):204-212. doi: 10.1001/jamaoncol.2018.4616.

8.

Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers.

Carmona Matos DM, Jang S, Hijaz B, Chang AW, Lloyd RV, Chen H, Jaskula-Sztul R.

Surgery. 2019 Jan;165(1):64-68. doi: 10.1016/j.surg.2018.05.077. Epub 2018 Nov 8.

PMID:
30415874
9.

Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs.

Hardin H, Helein H, Meyer K, Robertson S, Zhang R, Zhong W, Lloyd RV.

Lab Invest. 2018 Sep;98(9):1133-1142. doi: 10.1038/s41374-018-0065-0. Epub 2018 Jul 2.

10.

Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features.

Nikiforov YE, Baloch ZW, Hodak SP, Giordano TJ, Lloyd RV, Seethala RR, Wenig BM.

JAMA Oncol. 2018 Aug 1;4(8):1125-1126. doi: 10.1001/jamaoncol.2018.1446. No abstract available.

11.

The phrase NIFTP accentuates, rather than resolves, the current issues with thyroid neoplasia classification-reply.

Lloyd RV.

Hum Pathol. 2018 Sep;79:223. doi: 10.1016/j.humpath.2018.02.029. Epub 2018 Jun 4. No abstract available.

PMID:
29879401
12.

Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): Achieving Better Agreement By Refining Diagnostic Criteria.

Alves VAF, Kakudo K, LiVolsi V, Lloyd RV, Nikiforov YE, Nosé V, Papotti M, Thompson LDR.

Clinics (Sao Paulo). 2018 May 21;73:e576. doi: 10.6061/clinics/2018/e576. No abstract available.

13.

Recent Advances in the Classification of Low-grade Papillary-like Thyroid Neoplasms and Aggressive Papillary Thyroid Carcinomas: Evolution of Diagnostic Criteria.

Guo Z, Ge M, Chu YH, Asioli S, Lloyd RV.

Adv Anat Pathol. 2018 Jul;25(4):263-272. doi: 10.1097/PAP.0000000000000198. Review.

PMID:
29762157
14.

The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Lloyd RV, Asa SL, LiVolsi VA, Sadow PM, Tischler AS, Ghossein RA, Tuttle RM, Nikiforov YE.

Hum Pathol. 2018 Apr;74:1-4. doi: 10.1016/j.humpath.2017.12.027. Epub 2018 Jan 16. No abstract available.

PMID:
29339178
15.

Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma.

Zhang R, Hardin H, Huang W, Buehler D, Lloyd RV.

Endocr Pathol. 2018 Mar;29(1):1-8. doi: 10.1007/s12022-017-9507-2.

PMID:
29280051
16.

Annual review issue: An overview of 50 years of progress in endocrine pathology.

Lloyd RV, McNicoll AM.

Histopathology. 2018 Jan;72(1):4-5. doi: 10.1111/his.13289. No abstract available.

PMID:
29239043
17.

AKT activity is elevated in aggressive thyroid neoplasms where it promotes proliferation and invasion.

Matson DR, Hardin H, Buehler D, Lloyd RV.

Exp Mol Pathol. 2017 Dec;103(3):288-293. doi: 10.1016/j.yexmp.2017.11.009. Epub 2017 Nov 21.

PMID:
29169802
18.

Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma).

Rush PS, Rosenbaum JN, Roy M, Baus RM, Bennett DD, Lloyd RV.

J Cutan Pathol. 2018 Feb;45(2):129-135. doi: 10.1111/cup.13079. Epub 2017 Dec 17.

PMID:
29148079
19.

MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.

Chu YH, Hardin H, Schneider DF, Chen H, Lloyd RV.

Exp Mol Pathol. 2017 Oct;103(2):229-236. doi: 10.1016/j.yexmp.2017.10.002. Epub 2017 Oct 26.

PMID:
29107050
20.

Analysis of miR-96 and miR-133a Expression in Gastrointestinal Neuroendocrine Neoplasms.

Mandal R, Hardin H, Baus R, Rehrauer W, Lloyd RV.

Endocr Pathol. 2017 Dec;28(4):345-350. doi: 10.1007/s12022-017-9504-5.

PMID:
29032398
21.

Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus?

Hernandez-Prera JC, Machado RA, Asa SL, Baloch Z, Faquin WC, Ghossein R, LiVolsi VA, Lloyd RV, Mete O, Nikiforov YE, Seethala RR, Suster S, Thompson LD, Turk AT, Sadow PM, Urken ML, Wenig BM.

Thyroid. 2017 Dec;27(12):1498-1504. doi: 10.1089/thy.2017.0280. Epub 2017 Nov 7.

PMID:
29020884
22.

Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review.

Ambrosi F, Righi A, Ricci C, Erickson LA, Lloyd RV, Asioli S.

Endocr Pathol. 2017 Dec;28(4):293-301. doi: 10.1007/s12022-017-9502-7. Review.

PMID:
29019044
23.

Encapsulated follicular variant of papillary thyroid cancer: are these tumors really benign?

Aburjania Z, Jang S, Montemayor-Garcia C, Lloyd RV, Schneider DF, Sippel RS, Chen H, Elfenbein DM.

J Surg Res. 2017 Aug;216:138-142. doi: 10.1016/j.jss.2017.04.020. Epub 2017 May 4.

24.

Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm.

Covach A, Patel S, Hardin H, Lloyd RV.

Endocr Pathol. 2017 Sep;28(3):207-212. doi: 10.1007/s12022-017-9490-7.

PMID:
28660408
25.

Small cell carcinoma of the head and neck: An analysis of the National Cancer Database.

Pointer KB, Ko HC, Brower JV, Witek ME, Kimple RJ, Lloyd RV, Harari PM, Baschnagel AM.

Oral Oncol. 2017 Jun;69:92-98. doi: 10.1016/j.oraloncology.2017.04.009. Epub 2017 Apr 25.

26.

The evolving concept of cancer stem-like cells in thyroid cancer and other solid tumors.

Hardin H, Zhang R, Helein H, Buehler D, Guo Z, Lloyd RV.

Lab Invest. 2017 Oct;97(10):1142-1151. doi: 10.1038/labinvest.2017.41. Epub 2017 Apr 10. Review.

27.

Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.

Jang S, Yu XM, Montemayor-Garcia C, Ahmed K, Weinlander E, Lloyd RV, Dammalapati A, Marshall D, Prudent JR, Chen H.

Oncotarget. 2017 Apr 11;8(15):24457-24468. doi: 10.18632/oncotarget.14904.

28.

Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma.

Morandi L, Righi A, Maletta F, Rucci P, Pagni F, Gallo M, Rossi S, Caporali L, Sapino A, Lloyd RV, Asioli S.

Endocr Relat Cancer. 2017 Feb;24(2):107-117. doi: 10.1530/ERC-16-0546. Epub 2017 Jan 6.

PMID:
28062544
29.

Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis.

Somnay YR, Yu XM, Lloyd RV, Leverson G, Aburjania Z, Jang S, Jaskula-Sztul R, Chen H.

Cancer. 2017 Mar 1;123(5):769-782. doi: 10.1002/cncr.30403. Epub 2016 Nov 2.

30.

About RAS mutation-specific immunohistochemistry in formalin-fixed, paraffin-embedded tumor samples-reply.

Guo Z, Lloyd RV.

Hum Pathol. 2017 Feb;60:209. doi: 10.1016/j.humpath.2016.06.028. Epub 2016 Oct 13. No abstract available.

PMID:
27746272
31.

MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR.

Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV.

Endocr Pathol. 2017 Mar;28(1):7-12. doi: 10.1007/s12022-016-9453-4.

32.

Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues.

Xu J, Hardin H, Zhang R, Sundling K, Buehler D, Lloyd RV.

Endocr Pathol. 2016 Dec;27(4):271-275.

33.

Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.

Chu YH, Lloyd RV.

Endocr Pathol. 2016 Dec;27(4):312-324. Review.

PMID:
27539727
34.

Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections.

Guo Z, Lloyd RV.

Hum Pathol. 2016 Jul;53:168-77. doi: 10.1016/j.humpath.2016.03.013. Epub 2016 Apr 13. Review.

PMID:
27083401
35.

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.

Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA.

JAMA Oncol. 2016 Aug 1;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386.

36.

Generation of Novel Thyroid Cancer Stem-Like Cell Clones: Effects of Resveratrol and Valproic Acid.

Hardin H, Yu XM, Harrison AD, Larrain C, Zhang R, Chen J, Chen H, Lloyd RV.

Am J Pathol. 2016 Jun;186(6):1662-73. doi: 10.1016/j.ajpath.2016.02.003. Epub 2016 Apr 7.

37.

Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.

Gertz RJ, Nikiforov Y, Rehrauer W, McDaniel L, Lloyd RV.

Arch Pathol Lab Med. 2016 Feb;140(2):134-9. doi: 10.5858/arpa.2014-0612-OA.

PMID:
26910217
38.

Non-Coding RNAs in Thyroid Cancer.

Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV.

Endocr Pathol. 2016 Mar;27(1):12-20. doi: 10.1007/s12022-016-9417-8. Review.

PMID:
26847830
39.

Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression.

Yu XM, Jaskula-Sztul R, Georgen MR, Aburjania Z, Somnay YR, Leverson G, Sippel RS, Lloyd RV, Johnson BP, Chen H.

Clin Cancer Res. 2016 Jul 15;22(14):3582-92. doi: 10.1158/1078-0432.CCR-15-1749. Epub 2016 Feb 4.

40.

Prevention of trauma-induced cochlear fibrosis using intracochlear application of anti-inflammatory and antiproliferative drugs.

Jia H, François F, Bourien J, Eybalin M, Lloyd RV, Van De Water TR, Puel JL, Venail F.

Neuroscience. 2016 Mar 1;316:261-78. doi: 10.1016/j.neuroscience.2015.12.031. Epub 2015 Dec 21.

PMID:
26718602
41.

An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma.

Papathomas TG, Pucci E, Giordano TJ, Lu H, Duregon E, Volante M, Papotti M, Lloyd RV, Tischler AS, van Nederveen FH, Nose V, Erickson L, Mete O, Asa SL, Turchini J, Gill AJ, Matias-Guiu X, Skordilis K, Stephenson TJ, Tissier F, Feelders RA, Smid M, Nigg A, Korpershoek E, van der Spek PJ, Dinjens WN, Stubbs AP, de Krijger RR.

Am J Surg Pathol. 2016 Apr;40(4):569-76. doi: 10.1097/PAS.0000000000000574.

42.

INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms.

Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV.

Am J Clin Pathol. 2015 Oct;144(4):579-91. doi: 10.1309/AJCPGZWXXBSNL4VD.

PMID:
26386079
43.

Analysis of Amyloid in Medullary Thyroid Carcinoma by Mass Spectrometry-Based Proteomic Analysis.

Erickson LA, Vrana JA, Theis J, Rivera M, Lloyd RV, McPhail E, Zhang J.

Endocr Pathol. 2015 Dec;26(4):291-5. doi: 10.1007/s12022-015-9390-7.

PMID:
26304852
44.

Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.

Guo Z, Lloyd RV.

Adv Anat Pathol. 2015 Sep;22(5):283-93. doi: 10.1097/PAP.0000000000000086. Review.

PMID:
26262510
45.

In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.

Guo Z, Hardin H, Montemayor-Garcia C, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV.

Endocr Pathol. 2015 May;26(2):157-63. doi: 10.1007/s12022-015-9363-x.

PMID:
25771986
46.

Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.

Starenki D, Hong SK, Lloyd RV, Park JI.

Oncogene. 2015 Aug 27;34(35):4624-34. doi: 10.1038/onc.2014.392. Epub 2014 Dec 1.

47.

Pancreatic Neuroendocrine Neoplasms.

Rosenbaum JN, Lloyd RV.

Surg Pathol Clin. 2014 Dec;7(4):559-75. doi: 10.1016/j.path.2014.08.005. Epub 2014 Nov 8. Review.

PMID:
26837555
48.

The diagnostic utility of combination of HMGA2 and IMP3 qRT-PCR testing in thyroid neoplasms.

Jin L, Lloyd RV, Henry MR, Erickson LA, Sebo TJ, Rumilla KM, Zhang J.

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):36-43. doi: 10.1097/PAI.0000000000000031.

PMID:
25356939
49.

Novel approaches in anaplastic thyroid cancer therapy.

Hsu KT, Yu XM, Audhya AW, Jaume JC, Lloyd RV, Miyamoto S, Prolla TA, Chen H.

Oncologist. 2014 Nov;19(11):1148-55. doi: 10.1634/theoncologist.2014-0182. Epub 2014 Sep 26. Review.

50.

Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer.

Schneider DF, Elfenbein D, Lloyd RV, Chen H, Sippel RS.

Ann Surg Oncol. 2015 Jan;22(1):158-63. doi: 10.1245/s10434-014-3964-3. Epub 2014 Aug 5.

Supplemental Content

Loading ...
Support Center